References
- Gabizon A., Barenholz Y. Adriamycin-containing liposomes in cancer chemotherapy. Drug Carriers: Recent Trends and Progress, G. Gregoriadis. John Wiley, London 1988; 365–379
- Storm G., Roerdink F.H., Steerenberg P.A., deJong W.H., Crommelin D.J. Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model. Cancer Res. 1987; 47: 3366–3372
- Senior J.H. Fate and behavior of liposomes in vivo: a review of controlling factors. CRC Crit. Rev. ther. Drug Carrier Syst. 1987; 3: 123–193
- Gabizon A. Liposomes as a drug delivery system in cancer chemotherapy. Drug Carrier Systems, F.H. Roerdink, A.M. Kroon. John Wiley, London 1989; 185–211
- Allen T.M., Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett. 1987; 223: 42–46
- Gabizon A., Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. U.S.A. 1988; 85: 6949–6953
- Gabizon A., Shiota R., Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J. Natl. Cancer Inst. 1989; 81: 1484–1488
- Gabizon A., Goren D., Fuks Z., Meshorer A., Barenholz Y. Superior therapeutic activity of liposome-associated Adriamycin in a murine metastatic tumor model. Br. J. Cancer 1985; 51: 681–689
- Gabizon A., Goren D., Barenholz Y. Investigations on the antitumor efficacy of liposome-associated doxorubicin in murine tumor models. isr. J. Med. Sci. 1988; 24: 512–517
- Gabizon A., Peretz T., Sulkes A., Amselem S., Ben-Yosef R., Ben-Baruch N., Catane R., Biran S., Barenholz Y. Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study. Eur. J. Cancer Clin. Oncol. 1989; 25: 1795–1803
- Gabizon A., Meshorer A., Barenholz Y. Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J. Natl. Cancer Inst. 1986; 77: 459–469
- Druckmann S., Gabizon A., Barenholz Y. Separation of liposome-associated doxorubicin from nonliposome-a'ssociated doxorubicin in human plasma: implications for pharmacokinetic studies. Biochim. Biophys. Acta 1989; 980: 381–384
- Barenholz Y., Druckmann S., Cohen R., Amselem S., Sulkes A., Gabizon A. Complete pharmacokinetic analysis of liposome-associated doxorubicin in cancer patients. Proceedings, 16th Int'l Congress of Chemotherapy, 303. 1989; 1–3033
- Legha S.S., Benjamin R.S., Mackay R. Reduction of doxorubicin cardiotoxicity by prolonged continuous infusion. Ann. Intern. Med. 1982; 96: 133–139
- Gabizon A., Goren D., Fuks Z., Barenholz Y., Dagan A., Meshorer A. Enhancement of Adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers. Cancer Res. 1983; 43: 4730–4735